Cookie technology helps us bring you the best possible experience when you visit this website. Please let us know if you're happy to accept cookies. To learn more about our policy on cookies, please review our privacy policy via the link at the bottom of the page.

en:

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • ABBV-BH-00099-MC Approved September 2023

      ABBV-BH-00081-MC approved on September 2023

      Our therapy areas
      Oncology
      Immunology
      Medical Information
       
      Additional info
      Privacy Notice
      Terms Of Use

      This website is intended for Gulf Healthcare Professionals

      AbbVie Biopharmaceuticals GmbH.

       

      Suite 2901, U Bora Tower,Business Bay, Dubai, UAE

      PO Box:: 118052

      OFFICE : +971 4 5506100

      FAX: +971 4 5506101

      Your safety is our priority, we will remain always by your side; if you have any safety complaint, please contact us on:

      PV.MEA@Abbvie.com or Hotline: +971564135746/+96522052024

      For product quality complaints: 

      Email: eemea-pharmapqc@abbvie.com

       

       

      For Oman HCPs.

      Department of Pharmacovigilance & Drug information.

      Directorate General of pharmaceutical affairs and Drug control.

      Ministry of health, Sultanate of Oman

      Phone Nos:: 22357687 / 22357686

      Fax: 22358489

      Email: Pharma-Vigil@moh.gov.om

      Website:www.moh.gov.om